Gemphire Therapeutics Inc (NASDAQ:GEMP) – Stock analysts at Jefferies Group boosted their FY2018 earnings estimates for Gemphire Therapeutics in a research report issued to clients and investors on Tuesday, Zacks Investment Research reports. Jefferies Group analyst M. Andrews now forecasts that the company will post earnings of ($1.93) per share for the year, up from their previous estimate of ($2.04). Jefferies Group also issued estimates for Gemphire Therapeutics’ FY2019 earnings at ($1.59) EPS, FY2020 earnings at ($1.47) EPS, FY2021 earnings at ($1.42) EPS and FY2022 earnings at ($0.45) EPS.
Several other analysts have also weighed in on the company. Roth Capital reissued a “buy” rating and issued a $30.00 target price on shares of Gemphire Therapeutics in a report on Friday, December 22nd. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $22.00 price objective on shares of Gemphire Therapeutics in a research note on Friday, October 27th. Zacks Investment Research lowered Gemphire Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 17th. HC Wainwright increased their price objective on Gemphire Therapeutics from $22.00 to $28.00 and gave the company a “buy” rating in a research note on Friday, January 26th. Finally, ValuEngine lowered Gemphire Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, February 8th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $22.75.
A number of large investors have recently modified their holdings of GEMP. Virtu Financial LLC acquired a new stake in Gemphire Therapeutics in the 4th quarter worth about $120,000. Advisory Services Network LLC acquired a new stake in Gemphire Therapeutics in the 2nd quarter worth about $139,000. Vanguard Group Inc. boosted its stake in Gemphire Therapeutics by 137.6% in the 2nd quarter. Vanguard Group Inc. now owns 30,898 shares of the company’s stock worth $399,000 after buying an additional 17,892 shares during the last quarter. Comerica Bank acquired a new stake in Gemphire Therapeutics in the 3rd quarter worth about $850,000. Finally, Cambridge Investment Research Advisors Inc. boosted its stake in Gemphire Therapeutics by 4.5% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 159,964 shares of the company’s stock worth $1,520,000 after buying an additional 6,900 shares during the last quarter. 21.22% of the stock is currently owned by hedge funds and other institutional investors.
In related news, insider Steven R. Ph.D. Gullans acquired 71,429 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were acquired at an average price of $7.00 per share, with a total value of $500,003.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 34.00% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: “Jefferies Group Comments on Gemphire Therapeutics Inc’s FY2018 Earnings (GEMP)” was reported by Week Herald and is the property of of Week Herald. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://weekherald.com/2018/02/23/fy2018-eps-estimates-for-gemphire-therapeutics-inc-lifted-by-analyst-gemp.html.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.